Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice

Randomized controlled trials (RCTs) have consistently shown glycemic and extra-glycemic benefits of long-acting injectable glucagon-like-peptide-1 receptor agonists (GLP-1RAs, liraglutide, albiglutide, exenatide once-weekly, dulaglutide, and semaglutide) in terms of reduction in the rates of cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales: Morieri, Mario Luca, Avogaro, Angelo, Fadini, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665457/
https://www.ncbi.nlm.nih.gov/pubmed/33204129
http://dx.doi.org/10.2147/DMSO.S216054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665457/
https://www.ncbi.nlm.nih.gov/pubmed/33204129
http://dx.doi.org/10.2147/DMSO.S216054

Ejemplares similares